Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Published:2019-01-24 Issue:3 Volume:109 Page:292-298
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Sakurai Masatoshi,Kikuchi Taku,Karigane Daiki,Kasahara Hidenori,Matsuki Eri,Hashida Risa,Yamane Yusuke,Abe Ryohei,Koda Yuya,Toyama Takaaki,Kato Jun,Shimizu Takayuki,Yokoyama Yuta,Suzuki Sayo,Nakamura Tomonori,Okamoto Shinichiro,Mori Takehiko

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-019-02596-z/fulltext.html

Reference29 articles.

1. Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:591–611.

2. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

3. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.

4. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.

5. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa;eJHaem;2024-07-31

2. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04

3. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

4. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12

5. The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms;Kidney International;2023-12